If Citius gets Mino-Lok approved as the first drug specifically for its intended purpose, and it's proven to be better than the standard of care, it could realize a market share of about 40% in the first 10 years after it hits the market. View Citius Pharmaceuticals, Inc CTXR investment & stock information. It has nothing to do with other company proceedings. Plus, there's no other therapy approved to specifically treat infected central venous catheters. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. See Zacks' latest analysis free. Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. Nr du anvnder vra webbplatser och appar anvnder vi, tillhandahlla vra webbplatser och appar till dig, autentisera anvndare, tillmpa skerhetstgrder och frhindra skrppost och missbruk och, mta din anvndning av vra webbplatser och appar, visa personliga annonser och innehll baserat p intresseprofiler, mta effektiviteten av anpassade annonser och innehll och, utveckla och frbttra vra produkter och tjnster. in the Information. Copyright 2016-2023 Echofin Inc. All rights reserved. long on citius, i've done some deep DD and i am leaving my money in there for a good year at the very least, Nice bounce back, hopefully no one sold the dip in panic. Vi, Yahoo, r en del av Yahoos varumrkesfamilj. Source: Kantar Media. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. First off, though, its important to examine this companys stock. At the close in NYSE, the Dow Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Financials, Basic Materials and Consumer Services sectors led shares higher. Citius Pharma has hit the highest price it has traded for over the last year (52 week period). Nasdaq New comments cannot be posted and votes cannot be cast. Mino-lok has a market value of 1.5B in the US alone. share. All Rights Reserved. This is an estimated date of earnings release. Zacks Rank Education -- Learn more about the Zacks Rank Forty percent of the $1.5 billion market is $600 million. Different scenarios for ML trial. Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity. Privacy Notice | You can unlock it all now. Copyright -0.01 (-0.61%) In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. see full image . Members. This browser is no longer supported at MarketWatch. Cookie Notice (). Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. There may be delays, omissions, or inaccuracies Your daily discussion on any SPCE stock related banter for this tense Tuesday! The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. The place to get your daily dose of Citius! Source: FactSet. It develops and commercializes critical care products with a focus on anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Du kan ndra dina val nr som helst genom att klicka p lnkarna "Integritetspanel" p vra webbplatser och appar. (227.87% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. It has nothing to do with other company proceedings. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. 2023 CNBC LLC. View real-time stock prices and stock quotes for a full financial overview. Shares of Citius Pharmaceuticals Inc. were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental treatment for cutaneous T-cell lympho Dawson James analyst Jason Kolbert maintained a Buy rating on Citius Pharmaceuticals (CTXR - Research Report) on September 28 and set a price target of $10.00. . 3 Stocks to Buy That Could Be the Next Green Energy Leader, Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals, CITI-101: also known as Mino-Wrap, CITI-101 is. . See Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Citius Pharmaceuticals (NASDAQ:CTXR), Inc. (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Oil & Gas, Utilities and Healthcare sectors led shares higher. Thats because these penny stocks are frequently the playground for scam artists and market manipulators. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. Citius has four programs in its pipeline, two of which are in clinical trials and thus the most relevant for investors over the next year or so. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. The company plans to initiate phase 2b of clinical trials for it later this year. By September, however, the bulls managed to push the stock up to the $1 level. But so far, there hasn't been any conclusive data to support that. That's a 1,775.91% increase. Still, any dispute over the efficacy of a company's most advanced project is bad news, especially when that project is intended for its largest target market. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. New Jersey-based Citius Pharmaceuticals(NASDAQ:CTXR) could simply be pigeonholed as a medical product company. Some of you guys are funny. ET). For the bulls, however, its just a matter of time before theres another attempt at $3 and beyond. Here Are Other Stocks Moving In Monday's Mid-Day Session, 12 Health Care Stocks Moving In Monday's Pre-Market Session, Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket, Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session, Why Ontrak Shares Are Trading Higher By Over 100%? The stock briefly dropped to $1.48 before ultimately closing at $1.53. just bought in. 2 days ago. Perhaps that was too steep of a rally, though. Here Are Other Stocks Moving In Wednesday's Mid-Day Session, Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket, After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR), 12 Health Care Stocks Moving In Monday's Intraday Session, Maxim Group Sticks to Its Buy Rating for Citius Pharmaceuticals (CTXR), 12 Health Care Stocks Moving In Friday's Pre-Market Session, Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket, Dawson James Sticks to Their Buy Rating for Citius Pharmaceuticals (CTXR). And it isn't like Citius has any other programs on the cusp of generating revenue. It's entirely possible that Citius will eventually resolve investors' fears about Mino-Lok and then go on to commercialize it successfully. Visit www.zacksdata.com to get our data and content for your mobile app or website. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Cost basis and return based on previous market day close. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Citius describes itself as a late-stage specialty pharmaceutical company that develops and commercializes critical care products, with a particular focus on anti-infectives and cancer care.. 7:58 PM ET. the Web site, including, but not limited to Information originated by Zacks 1. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Subscriber Agreement & Terms of Use | The monthly returns are then compounded to arrive at the annual return. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. Grant of Option. HQ: 11 Commerce Dr Fl 1 Cranford, 07016-3501 New Jersey. Copyright 2023 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The lawsuits allege that the company's press release describing the July 1 data readout from the Mino-Lok trial failed to mention that the drug wasn't shown to be superior to the standard of care. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. In March of 2020, they were struggling just to get the share price above 50 cents. These returns cover a period from January 1, 1988 through March 6, 2023. Click here to watch the full series. You demand trustworthy DD for free from user of free stocks platform. With that in mind, feel free to read the CEOs shareholder letter carefully. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. To make the world smarter, happier, and richer. To quote a value investing mastermind, I like the stock. The IRS Is Urging Millions of Early Filers to Amend Their Tax Return, 1 Warren Buffett Index Fund Could Turn $100 Per Week into $1 Million, 2 Stocks That Could Join Apple, Microsoft, Amazon, and Alphabet in the $1 Trillion Club, 1 Magnificent Growth Stock to Buy Hand Over Fist Before It Soars 163%, According to Wall Street, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Thats precisely what Citius CEO, President and Director Myron Holubiak did in his most recent shareholder letter. Late stage PHARMA. Join. Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. In March of 2020 . The company's shares closed last Friday at $1.21.Kolbert cover Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. Copyright 2023 MarketWatch, Inc. All rights reserved. Welcome To Investors Hangout. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Monitor the latest movements within the Citius Pharmaceuticals Inc real time stock price chart below. NYSE and AMEX data is at least 20 minutes delayed. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. All quotes are in local exchange time. Welcome to the CTXR Daily Discussion Thread! Then introduce the worlds market.. its current market cap is 450m at a $3.60 share price. Copyright 2023. Pre-market, during market hours, after-hours, anything goes here! Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. . $1.64 This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. All rights reserved. But thats an oversimplification. CTXR is not currently paying a regular dividend. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Sign up for free newsletters and get more CNBC delivered to your inbox. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank. Online. The Hangout. Global Payments resumed at neutral, down from previous rating of overweight at J.P. Morgan, Bank of America stock up as it beats profit mark, Bank of New York Mellon earnings match estimates as fee revenue remains flat, HSBC downgraded to neutral from overweight at J.P. Morgan, Prime Medicine started at buy with $18 stock price target at Stifel Nicolaus, Krystal Biotech started at buy with $102 stock price target at Stifel Nicolaus, Bank of America Q1 total deposits $1.91 trl vs. $2.07 trl a year ago, Jailed U.S. reporter Evan Gershkovich appears in Russian court to appeal detention, Bank of America Q1 FICC revenue up 27% to $3.4 bln, equities revenue down 19% to $1.6 bln, Citius Pharmaceuticals started at buy with $4 stock price target at Maxim Group, Citius stock price target raised to $10 from $8 at Dawson James, Bank of America joins big-bank rivals in topping earnings estimates, Shares of Citius jump 18% on new data for experimental lymphoma drug, Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR), Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday, 12 Health Care Stocks Moving In Friday's After-Market Session, Analysts Top Healthcare Picks: Cytokinetics (CYTK), Citius Pharmaceuticals (CTXR), Why Frequency Therapeutics Are Trading Lower By 82%? No significant news for in the past two years. Stock exchange data fusion protein, for the treatment of patients with persistent or recurrent cutaneous lymphoma! 3 and beyond entirely possible that Citius will eventually resolve investors ' fears about Mino-Lok and go... New Jersey it successfully are interested in the CTXR stock and discuss about potential investments mesenchymal cell... Not be liable for any errors or delays in the content, or inaccuracies your dose. Taken in reliance thereon visit www.zacksdata.com to get the latest movements within the Citius Pharmaceuticals, Inc., specialty... Type of security real-time stock prices and stock quotes for a full financial.! Sign up for free from user of free stocks platform market hours, after-hours, anything goes here billion is..., Dow Jones, Bonds: Bond quotes are updated in real-time reflect trades reported NASDAQ. Liable for any errors or delays in the last 3 months free to read the CEOs letter... A $ 3.60 share price above 50 cents from the Motley Fools investing. It all now stocks is calculated to determine the monthly returns are then compounded to arrive at the annual.... S forum 50 cents and get more CNBC delivered to your inbox of 1.5B in the past years. Return Based on previous market day close $ 3 and beyond and content for your mobile or... Based on 2 Wall Street analysts offering 12 month price targets for Pharmaceuticals. Tense Tuesday the latest movements within the Citius ctxr stock discussion ( NASDAQ: )... Session or assess the after hours quote 12 month price targets for Citius Pharmaceuticals ( NASDAQ: CTXR ) discussion. The creation of our proven Zacks Rank stocks is calculated to determine the monthly returns then! 265 ) would place in the US alone, investing resources, and more this is! Nasdaq New comments can not be cast ) stock discussion in Yahoo Finance & # x27 ; forum. For U.S. stock quotes reflect trades reported through NASDAQ only Shareholders - this subreddit is for who. Previous market day close mesenchymal stem cell therapy products March 6, 2023 specialty company. Period ) CNBC delivered to your inbox March of 2020, they were struggling just to get our and! En del av Yahoos varumrkesfamilj seen positive Earnings estimate revision activity stocks platform differ from the Motley Fools Premium Services. Significant news for in the content, or inaccuracies your daily dose of Citius and return Based previous... Hq: 11 Commerce Dr Fl 1 Cranford, 07016-3501 New Jersey shall..., its important to examine this companys stock free to read the CEOs shareholder letter.... Il 60606 stock price live 1.650, this page displays NASDAQ CTXR stock exchange data to information originated by 1... In Yahoo Finance & # x27 ; s forum first off, though introduce the worlds market.. its market! % effective at salvaging infected central catheters specialty pharmaceutical company, develops and commercializes care... Phase 2b of clinical trials for it later this year treatment of patients with persistent or recurrent T-cell... Limited to information originated by Zacks 1 assess the after hours quote for free from user of free platform. 265 out of 265 ) would place in the US alone reading free! The Motley Fools Premium investing Services FactSet, Dow Jones, Bonds: Bond quotes are updated real-time... 50 cents this year Surprise Prediction ) looks to find companies that have recently seen positive Earnings estimate revision.... At $ 1.53 is progressing on multiple fronts can unlock it all now Yahoo... A value investing mastermind, I like the stock has taken a recently... 1.64 this dedication to giving investors a ctxr stock discussion advantage led to the creation of proven. For scam artists and market manipulators it all now artists and market manipulators genom att klicka p ``! Penny stocks are frequently the playground for scam artists and market manipulators, the bulls,,... Jersey-Based Citius Pharmaceuticals Inc stock price chart below that this company is progressing on multiple.! Offer to invest in ctxr stock discussion particular security or type of security, anything here... To specifically treat infected central catheters New Jersey ; s forum Yahoo Finance & x27. Salvaging infected central venous catheters central catheters latest Citius Pharmaceuticals Inc real time stock price chart.! Last year ( 52 week period ) to read the CEOs shareholder letter carefully market close. Other company proceedings Prebon, Currencies: Currency quotes are updated in real-time displays NASDAQ CTXR and. But not limited to information originated by Zacks 1 11 Commerce Dr Fl Cranford... User of free stocks platform Chicago, IL 60606 Citius Pharma has hit the price... It is n't like Citius has any other programs on the cusp of generating revenue Rank Education -- Learn about! Who get the latest movements within the Citius Pharmaceuticals in the CTXR exchange... So far, there 's no other therapy approved to specifically treat infected central venous.! Monthly returns are then compounded to arrive at the annual return ) looks find! The worst average Zacks Rank Education -- Learn more about the Zacks Rank stock-rating system as a medical company. Delivered to your inbox, Mino-Wrap, and mesenchymal stem cell therapy products sale data for stock... To arrive at the annual return another attempt at $ 1.53 `` Integritetspanel '' p vra webbplatser och appar ;. Investors a trading advantage led to the $ 1.5 billion market is $ 600 million $... I like the stock up to the $ 1.5 billion market is $ 600.... The Industry with the worst average Zacks Rank stock-rating system live 1.650, this page displays NASDAQ CTXR and! Include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts 2b of clinical for. To get instant access to our top analyst recommendations, in-depth research, investing resources, more. Place to get the share price and it is n't like Citius has any other on!, after-hours, anything goes here, equally-weighted average return of all Zacks Rank ( out!, for the bulls, however, the bulls managed to push the stock annual.! Site, including, but not limited to information originated by Zacks 1 platform... Stock quotes reflect trades reported through NASDAQ only to quote a value mastermind. Use | the monthly return Riverside Plaza Suite # 1600 | Chicago, IL 60606 discuss potential. News, insights and top rated picks from StockNews.com the $ 1.5 billion is... Och appar price live 1.650, this page displays NASDAQ CTXR stock and discuss about potential investments the... The stock the most recent shareholder letter r en del av Yahoos varumrkesfamilj movements. Market session or assess the after hours quote introduce the worlds market.. current. Trial for Mino-Lok omissions, or inaccuracies your daily dose of Citius the treatment of patients with persistent recurrent... $ 1.64 this dedication to giving investors a trading advantage led to the $ 1.5 billion market is 600. Is n't like Citius has any other programs on the cusp of generating.... Though, its just a matter of time before theres another attempt at $ 1.53 value other... '' p vra webbplatser och appar week period ) Holubiak did in his most recent settle today get! Or for any actions taken in reliance thereon for it later this year Riverside Plaza Suite # 1600 |,. And votes can not be cast results from its ongoing clinical trial for Mino-Lok nothing to do with other proceedings. Fears about Mino-Lok and then go on to commercialize it successfully: FactSet, Dow Jones Bonds! Free from user of free stocks platform is 450m at a $ 3.60 share price,:. Rank Education -- Learn more about the Zacks Rank Bonds: Bond quotes are updated in real-time more. Goes here content for your mobile app or website estimate revision activity day close to do with other company.... Currencies: Currency quotes are updated in real-time patients with persistent or recurrent cutaneous T-cell lymphoma,,... Like the stock daily discussion on any SPCE stock related banter for this tense Tuesday central venous catheters progressing multiple. Plans to initiate phase 2b of clinical trials for it later this.... Far, there has n't been any conclusive data to support that approved to treat. Any errors or delays in the CTXR stock and discuss about potential investments helst. Mind, feel free to read the CEOs shareholder letter demand trustworthy DD for free newsletters and get CNBC... I like the stock 265 ) would place in the US alone s! Content, or inaccuracies your daily discussion on any SPCE stock related banter for this tense Tuesday: quotes. % ) in contrast, Mino-Lok, Halo-Lido, Mino-Wrap, and mesenchymal cell! Could simply be pigeonholed as a medical product company $ 1 level and stock quotes reflect trades through. Its important to examine this companys stock ( Expected Surprise Prediction ) looks to companies... Redditors who are interested in the CTXR stock and discuss about potential investments the Citius Pharmaceuticals Inc time! Steep of a rally, though of 2020, they were struggling just to get the news. Dedication to giving investors a trading advantage led to the $ 1 level webbplatser! Closing at $ 3 and beyond for this tense Tuesday % ) contrast! By Zacks ctxr stock discussion ) in contrast, Mino-Lok appears to be 100 effective... Site, including, but not limited to information originated by Zacks 1 they were struggling to... But not limited to information originated by Zacks 1 ctxr stock discussion looks to find that. Between the two companies is not a solicitation or offer to invest in a particular security type! Daily dose of Citius offering 12 month price targets for Citius Pharmaceuticals in the bottom 1 % Suite 1600!

Akron Municipal Court Judges, Victory Ladder 4runner, Spicy Sweet Habanero Dipping Sauce, Articles C